49 / 50
Controlling Chemotherapy Associated Emesis
- Comments -
• New Agents provide greater convenience and flexibility in variety of emetic settings and address
problems in prevention of emesis
– New choices are found for ease of adherence, risk and benefit
• New indications are based on evidence and enlarge areas of needed protection
– Steroids on Day 1 only in many settings
– Addition of NK
1
agents with cisplatin, carboplatin, and “AC” to affect quality of life and resource utilization
– Delayed emesis: Simplification of regimens and less use of 5HT
3
agents
– Single dose NEPA addresses each of these issues
• Issues for guideline committees to address include:
– A better focus on evidence or at least highlight evidence versus opinion
– Simplification of the prevention of emesis
• The control of emesis continues to improve: applying evidence-based guidelines and conducting
quality research are priorities